Skip to main content
. 2013 Apr 3;2013:347520. doi: 10.1155/2013/347520

Table 2.

Discontinuation rates by intervention and study type.

MMF MTX AZA IVC Oral CYC CsA
RCTs (n = 11) 1.4–13% 12.2% 2.3–20% 2.9–7.7% 9.7–44.4% 13.9–17.0%
Observational (n = 11) 0–16.7% 8.3–11% 19–21.8% 1.9–18.8% 5.6% 16.1%

AZA: azathioprine; CsA: cyclosporine; CYC: cyclophosphamide; IVC: intravenous cyclophosphamide; MMF: mycophenolate mofetil; MTX: methotrexate; N/A: not available; RCT: randomized controlled trial.